FDA approves GSK lung cancer drug acquired through Nuvalent deal

The U.S. Food and Drug Administration granted accelerated approval to GSK’s neladalkib for lung cancer. The kinase inhibitor came through GSK’s $10.6B acquisition of Nuvalent, linking the regulatory decision to that transaction.

The approval permits U.S. commercialization of the therapy and supports Bloomberg’s characterization that it validates GSK’s Nuvalent acquisition.

Sources